NCT06140953
Benefits of Trimetazidine in MAFLD Pateints
Evaluation of Potential Benefits of Trimetazidine in the Management of Pateints With Metabolic Associated Fatty Liver Disease ( MAFLD)
October 6 University·Phase 2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Non-Alcoholic Fatty Liver Disease
- Drug/Device/Intervention
- conventional treatment
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- October 6 University
- Location
- Giza, Egypt
Timeline & enrollment
- Phase
- Phase 2
- Start date
- Dec 10, 2023
- End date
- Sep 01, 2025
- Enrollment
- 60 participants
Primary outcome
incidence in mafld,incidence in mafld,incidence in mafld
Summary
Objective of this study is to determine the clinical benefits of trimetazidine in improvement
 of MAFLD
ICD-10 classifications
Alcoholic fatty liverAlcoholic liver disease, unspecifiedAlcoholic liver diseaseLiver disease, unspecifiedAlcoholic cirrhosis of liver
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06140953
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06140953 through Pure Global AI's free database. This Phase 2 trial is sponsored by October 6 University and is currently Recruiting. The study focuses on Non-Alcoholic Fatty Liver Disease. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.